Corvus Pharmaceuticals (CRVS) Balance Sheet: Assets & Liabilities

Corvus Pharmaceuticals (CRVS) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Corvus Pharmaceuticals reported total assets of $71.12M and total liabilities of $9.91M. Shareholders' equity was $61.20M, up 87.9% from $32.57M a year earlier. Total debt stood at $937.00K against $56.75M in cash and short-term investments, a net cash position of $55.81M. That puts debt-to-equity at 0.02, compared with 0.03 a year earlier.

Corvus Pharmaceuticals Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Corvus Pharmaceuticals, Inc. (CRVS) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017
Current Assets
Cash and Cash Equivalents	4.58	8.74	12.62	13.16	63.46	16.46	5.15	114.60	90.06
Short-Term Investments	52.17	43.22	14.53	29.14	5.99	27.80	72.83	0.00	0.00
Cash & Short-Term Investments	56.75	51.96	27.15	42.30	69.45	44.26	77.98	114.60	90.06
Accounts Receivable	0.04	0.08	0.03	0.59	0.51	0.09	0.33	0.34	0.13
Inventory	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.60	-0.85
Other Current Assets	0.32	0.55	0.22	0.77	0.13	0.40	1.03	0.66	1.05
Total Current Assets	58.21	54.41	27.96	43.66	71.31	45.34	79.34	114.60	90.06
Non-Current Assets
Property, Plant & Equipment (Net)	1.06	1.33	1.39	2.57	3.64	2.55	3.79	2.18	2.67
Long-Term Investments	10.99	12.54	16.12	21.88	34.27	37.23	0.00	0.00	0.00
Other Non-Current Assets	0.86	0.63	0.09	0.13	0.24	0.41	0.51	1.46	2.05
Total Non-Current Assets	12.91	14.50	17.60	24.58	38.14	40.19	4.30	3.64	4.72
Total Assets	71.12	68.91	45.55	68.24	109.46	85.53	83.65	118.23	94.78
Current Liabilities
Accounts Payable	2.49	2.58	1.53	1.98	1.57	3.47	2.45	2.00	3.45
Short-Term Debt	0.40	0.19	1.37	1.23	1.05	1.08	0.88	0.00	0.00
Accrued Liabilities	5.61	2.62	3.04	7.55	5.11	7.42	-	-	-
Other Current Liabilities	0.24	29.20	0.25	0.16	0.12	0.18	6.90	5.03	5.52
Total Current Liabilities	9.38	35.40	6.87	10.75	9.69	12.15	10.23	7.90	9.94
Non-Current Liabilities
Long-Term Debt	0.53	0.94	0.00	1.37	2.60	1.23	2.31	0.00	0.00
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.87	0.97
Total Non-Current Liabilities	0.53	0.94	0.00	1.37	2.60	1.23	2.31	0.87	0.97
Total Liabilities	9.91	36.34	6.87	12.13	12.29	13.38	12.54	7.90	9.94
Stockholders' Equity
Common Stock	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00
Retained Earnings	-412.29	-397.01	-334.72	-307.69	-266.38	-223.14	-217.15	-170.47	-123.53
Accumulated Other Comprehensive Income	-0.90	-1.29	-0.97	-0.56	1.87	0.00	0.03	-0.03	-0.04
Additional Paid-in Capital	474.39	430.86	374.36	364.36	361.67	295.28	288.22	280.84	208.41
Shares Outstanding	74.70	67.90	49.04	46.55	46.55	-	-	-	-
Total Stockholders' Equity	61.21	32.57	38.68	56.12	97.16	72.15	71.11	110.34	84.84
Total Liabilities & Equity	71.12	68.91	45.55	68.24	109.46	85.53	83.65	118.23	94.78

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Corvus Pharmaceuticals Balance Sheet

How much debt does Corvus Pharmaceuticals have?

Corvus Pharmaceuticals had total debt of $937.00K as of Dec 31, 2025, against $56.75M in cash and short-term investments. Its debt-to-equity ratio was 0.02. Total debt was $1.12M a year earlier.

What are Corvus Pharmaceuticals's total assets?

Corvus Pharmaceuticals reported total assets of $71.12M as of Dec 31, 2025, up 3.2% from $68.91M a year earlier. Total liabilities were $9.91M.

What is Corvus Pharmaceuticals's shareholders' equity?

Corvus Pharmaceuticals's shareholders' equity was $61.20M as of Dec 31, 2025, or about $0.82 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition